Concurrent Investment Advisors LLC Purchases 15,667 Shares of TG Therapeutics, Inc. $TGTX

Concurrent Investment Advisors LLC boosted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 241.9% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 22,143 shares of the biopharmaceutical company’s stock after buying an additional 15,667 shares during the period. Concurrent Investment Advisors LLC’s holdings in TG Therapeutics were worth $1,217,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Danske Bank A S purchased a new position in shares of TG Therapeutics in the third quarter valued at about $25,000. EverSource Wealth Advisors LLC boosted its stake in shares of TG Therapeutics by 51.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 365 shares during the period. Hantz Financial Services Inc. grew its position in shares of TG Therapeutics by 82.7% during the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 560 shares in the last quarter. Truvestments Capital LLC grew its position in shares of TG Therapeutics by 172.4% during the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 1,026 shares in the last quarter. Finally, Kemnay Advisory Services Inc. bought a new stake in TG Therapeutics during the 4th quarter valued at approximately $52,000. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Price Performance

TGTX stock opened at $55.39 on Friday. TG Therapeutics, Inc. has a 52 week low of $26.76 and a 52 week high of $59.30. The firm has a market capitalization of $8.48 billion, a P/E ratio of 20.22, a price-to-earnings-growth ratio of 2.34 and a beta of 1.67. The company has a fifty day simple moving average of $53.63 and a two-hundred day simple moving average of $43.61. The company has a quick ratio of 3.72, a current ratio of 4.27 and a debt-to-equity ratio of 1.23.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The business had revenue of $240.34 million during the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The business’s quarterly revenue was up 70.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.17 earnings per share. Analysts anticipate that TG Therapeutics, Inc. will post 0.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on TGTX. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a report on Wednesday, July 29th. Bank of America increased their price objective on shares of TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a report on Tuesday, July 7th. Zacks Research cut shares of TG Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday. HC Wainwright reissued a “buy” rating and issued a $78.00 target price on shares of TG Therapeutics in a report on Tuesday, September 1st. Finally, B. Riley Financial boosted their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $63.00.

About TG Therapeutics

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell diseases and autoimmune disorders. The company’s research and development programs are centered on therapies that target B cells, which play an important role in several immune-mediated conditions.

TG Therapeutics’ principal product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.